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Objectives: To compare levels of a marker of lipid peroxidation (thiobarbituric acid reactive
substances, TBARS) and brain-derived neurotrophic factor (BDNF) in umbilical cord blood (UCB)
between newborns exposed to crack/cocaine in utero (exposed newborns [EN], n=57) and non-
exposed newborns (NEN, n=99), as well as in maternal peripheral blood at delivery.
Methods: This was a cross-sectional study. Potential confounders, including perinatal parameters,
psychopathology, and use of other substances, were assessed.
Results: After adjusting for potential confounders, adjusted mean BDNF was significantly higher in
EN (3.86 ng/mL, 95% confidence interval [95%CI] 2.29-5.43) than in NEN (0.85 ng/mL, 95%CI
0.47-1.23; p o 0.001; Cohen effect size: 1.12), and significantly lower in crack/cocaine mothers than
in control mothers (4.03 ng/mL, 95%CI 2.87-5.18 vs. 6.67 ng/mL, 95%CI 5.60-7.74; p = 0.006). The
adjusted mean TBARS level was significantly lower in EN (63.97 mM MDA, 95%CI 39.43-88.50) than
NEN (177.04 mM MDA, 95%CI 140.93-213.14; p o 0.001; effect size = 0.84), with no difference
between mother groups (p = 0.86).
Conclusions: The changes in TBARS levels observed in EN suggest that fetuses exposed to cocaine
mobilize endogenous antioxidant routes since very early stages of development. The increase in BDNF
levels in EN might indicate changes in fetal development, whereas the changes in BDNF levels in
mothers provide evidence of the complex metabolic processes involved in drug use during pregnancy.
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Introduction
Cocaine and some of its metabolites are stored in both
the myometrium and the placental membrane, and are
continuously delivered into the amniotic fluid, exposing
the fetus to a state of slow-release cocaine delivery.1
Prenatal drug exposure affects neonatal brain functional
connectivity, with cocaine having a specific effect on the
amygdala-frontal network.2 The pathways involved in
such changes remain unclear. Brain-derived neurotrophic
factor (BDNF) and other neurotrophic factors can play a
crucial role in the development and maintenance of the
central nervous system, and might influence the formation
and elimination of neural connections.3 It is reasonable
to consider that intrauterine cocaine exposure (IUCE)
may disrupt this process. Cocaine also contributes to an
imbalance in the oxidative/antioxidant system by increas-
ing the production of reactive oxygen species (ROS)4 and
disrupting the antioxidant system in the embryonic
period.5 Thus, IUCE could damage neurodevelopment
since very early embryonic stages. Despite some studies
on BDNF and oxidative stress (OE) in crack/cocaine-
exposed adults and animal models, no data are available
for newborns with a history of IUCE, nor for pregnant
women. Thus, the purpose of this study was to compare
OS (represented by lipid peroxidation, measured by
thiobarbituric acid reactive substances, TBARS) and
levels of BDNF in umbilical cord blood (UCB) from
newborns with IUCE (exposed newborns [EN]) and non-
exposed newborns (NEN), as well as in their respective
mothers, in the immediate postpartum period.
Methods
Data were collected at Hospital de Clı´nicas de Porto
Alegre (HCPA) and Hospital Materno Infantil Presidente
Vargas (HMIPV), in the city of Porto Alegre, state of
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Rio Grande do Sul, Brazil. All mothers provided written
informed consent, and the project was approved by the
Ethics Committees of both hospitals.
This was a cross-sectional study. The predictive var-
iable was history of crack/cocaine use/exposure and the
outcome measures were serum levels of BDNF and
TBARS in UCB and in maternal peripheral blood at deli-
very. Participants were mother/newborn dyads exposed
to crack/cocaine who underwent consecutive sampling at
HMIPV. Control newborn/mother samples were obtained
from a group of pregnant women who participated in the
HCPA Umbilical Cord and Placental Blood Bank (Banco
de Sangue de Corda˜o Umbilical e Placenta´rio) project,
according to the Foundation for the Accreditation of
Cellular Therapy (FACT) criteria.6 The maternal inclusion
criteria for the EN group were crack/cocaine use and age
18-45 years, and the exclusion criteria were inability to
understand and complete the psychiatric questionnaires.
The inclusion and exclusion criteria for controls relied on
FACT criteria. All mothers included in the control group were
confirmed as non-drug users by history and urinary tests
(Bioeasy® cocainetest, Aleret, Belo Horizonte, Brazil).
Tobacco use was not an exclusion criterion for controls.
Controls could not have abuse or dependence of alcohol
or other drugs, according to the MINI interview. The poten-
tial confounders were: maternal intelligence quotient (IQ)
(Wechsler Adult Intelligence Scale-III [WAIS-III])7 and
psychopathology (Mini International Neuropsychiatric Inter-
view [MINI], Brazilian version 5.0.0/DSM-IV/Current8); use
of other psychoactive substances (Alcohol, Smoking and
Substance Involvement Screening Test [ASSIST]9); socio-
demographic data (age, self-reported ethnicity, marital status,
educational attainment); and perinatal and obstetric data.
The following neonatal variables were obtained by review of
medical records: weight, Apgar score at 1 and 5 minutes,
gestational age (GA) at neonatal examination, sex, and
classification for GA. Data on the clinical status of the mother
for relevant infections (syphilis, HIV, and/or hepatitis C),
mode of delivery, and prenatal care were also collected
from medical records. Blood collection and processing and
BDNF and TBARS measurement were performed as usual
in our laboratory.10 The main outcome measure was asses-
sed by generalized linear model (GLM) analyses (gamma
distribution), while confounders were chosen on the basis
of statistical criteria (association with both study factor and
outcome measure at a significance level of p p 0.2). The
accepted significance level was p p 0.05. Data were
processed and analyzed in PASW Statistics 18.0.
Results
The sample comprised 57 EN and 99 NEN. Selected
characteristics of the newborns and their mothers are
shown in Table 1. No mother reported use of intravenous
drugs, club drugs, or hallucinogens. There was no dif-
ference between groups for gestational age (p = 0.37),
infant gender (p = 0.72), maternal age (p = 0.39), or
cesarean delivery (p = 1).
In the GLM analyses for BDNF in UCB, results were
adjusted for intensity of alcohol, tobacco, and cannabis
use in the last 3 months, presence of any maternal
infection, infant weight, and marital status. Adjusted
mean BDNF levels were significantly higher in newborns
exposed to crack/cocaine in utero (3.86 ng/mL, 95%CI
2.29-5.43) than in NEN (0.85 ng/mL, 95%CI 0.47-1.23;
po 0.001; Wald = 20.75), as shown in Table 1. The Cohen
effect size was 1.12 (very large). No variable other than
crack/cocaine exposure was significant. For analysis of
TBARS levels in UCB, results were adjusted for intensity of
alcohol, tobacco, and cannabis use in the last 3 months,
presence of any maternal psychopathology, maternal infec-
tious disease, prenatal care, marital status, and estimated
IQ. Variables that did not contribute to the model were
withdrawn in descending order of p-value. Mean adjus-
ted TBARS levels were significantly lower in newborns
exposed to crack/cocaine in utero (63.97 mM MDA, 95%CI
39.43-88.50) than in NEN (177.04 mM MDA, 95%CI
140.93-213.14; p o 0.001; Wald = 19.71), with a large
effect size (0.84). In addition to crack/cocaine exposure,
presence of any maternal psychopathology (p = 0.04,
Wald = 4.42) and estimated IQ (po 0.001; Wald = 17.62)
were also significant. According to GLM analysis, with a
model including intensity of cannabis use in the last
3 months, presence of any maternal psychopathology, and
5-minute Apgar score, TBARS measures in the immediate
postpartum period were not significantly different between
crack/cocaine-using mothers (30.52 mMMDA, 95%CI 17.79-
43.25) and control mothers (29.21 mM MDA, 95%CI 23.95-
34.47; p = 0.86). However, there was a difference between
groups for postpartum BDNF levels, which were significantly
lower in crack/cocaine users than in controls (adjusted for
intensity of use of alcohol and tobacco; 4.03 ng/mL, 95%CI
2.87-5.18 vs. 6.67 ng/mL, 95%CI 5.60-7.74, Wald = 7.52;
p = 0.006).
Discussion
In our study, we were able to demonstrate differences in a
general state of oxidative stress, as measured by TBARS,
in neonates exposed to crack/cocaine in utero. Among
possible explanations, cocaine and amphetamine regu-
lated transcript (CART), an endogenous antioxidant sti-
mulated by dopamine presence, should be considered.
According to animal models, CART is expressed very
early during embryonic neurodevelopment,11 being more
present in the cortex, nucleus accumbens, and ventral
tegmental area and decreasing progressively in expres-
sion as the fetus develops.12 Dopaminergic stimulation,
as seen in crack/cocaine dependence, is a regulator of
CART expression. In our study, high levels of dopamine
due to maternal crack/cocaine intake might have affected
fetal homeostasis. The maturational decrease in CART
levels, among other factors, could help explain the ab-
sence of difference in TBARS levels between exposed
and control pregnant women.
BDNF plays a major role in cellular plasticity during
development and maturation of the brain. In agreement
with our results, young rats treated with stimulants exhi-
bited increased BDNF protein levels in the prefrontal
cortex compared to a saline-treated group.13 In our study,
higher levels of BDNF in exposed newborns might indi-
cate an acute stress reaction. Increased BDNF in this
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scenario might represent as a compensatory search for
neuroprotection.10 However, this does not necessarily
imply a better outcome for these children. In an animal
model, the long-term effect of high BDNF levels has been
suggested to affect neuronal migration and maturation
through different developmental periods.14 These changes
could, in fact, cause impairment in brain function in adult
life, which would help understand the complex pathway to
cognitive and behavioral problems seen in exposed off-
spring.14 Pregnancy, however, is characterized by several
metabolic changes that interact with circulating BDNF
levels. In usual circumstances, BDNF levels are expected
to be lowest in the first trimester of pregnancy and increase
thereafter.15 In puerperal women, decreased BDNF levels
might indicate chronicity of stressor exposure, as BDNF
decreases in chronic stress.16
The present study has some limitations. While our
chosen measure for oxidative imbalance (TBARS) is widely
used, other markers are available. Our sample was com-
posed of pregnant polydrug users; this increases the
external validity of the study and, on multivariate analysis,
the data were adjusted for use of other substances. We did
not measure maternal body mass index because, although
it is a good measure for the pre-gestational stage, it is not
useful when data collection takes place at the time of
delivery, as in our study. Additionally, it is important to note
that our sample of cases comprised a difficult-to-reach
population of women who received, for instance, incom-
plete prenatal care. Finally, as this was a cross-sectional
study, we cannot establish causal associations. Specific
strengths of our study included measuring TBARS and
BDNF in UCB, before newborns had been exposed to
other stressors. To the best of our knowledge, ours is the
first report of these biomarkers in newborns with a history
of crack/cocaine exposure.
Taken together, our findings in EN and their mothers
could be understood in the same direction, suggesting
age-dependent neuroprotective changes in the oxidation-
reduction status (redox) (lower TBARS in EN; no signi-
ficant difference among women in the postpartum period)
and a neuroplastic response (higher BDNF in EN; lower
BDNF among women in the postpartum period) promoted
by crack/cocaine. Our data suggest a need for further
investigations into the fetal endogenous antioxidant
Table 1 Sociodemographic, clinical characteristics, TBARS and BDNF levels of crack/cocaine-exposed mother-infant pairs
and controls
Cases (n=57) Controls (n=99) p-value
Infant variables, mean (SD)
Weight (g) 2,882.15 (473.32) 3,144.80 (439.39) 0.001
Apgar, 1-minute 7.8 (2.12) 8.41 (1.31) 0.06
Apgar, 5-minute 8.94 (1.24) 9.38 (0.74) 0.007
Maternal variables
Ethnicity, n (%)
White 17 (32.1) 74 (76.3) o 0.001
Nonwhite 36 (67.9) 23 (23.7)
IQ, mean (SD) 77.39 (8.75) 84.17 (9.59) o 0.001
Educational attainment, n (%)
Some primary, completed primary, or some secondary 39 (81.3) 51 (53.1)
Completed secondary, some higher, or completed higher 9 (18.8) 45 (53.1) 0.002
Prenatal care, n (%)* 36 (73.5) 99 (100) o 0.001
Presence of infectious diseases (syphilis, HIV, and/or hepatitis C), n (%)* 26 (46.4) 0 o 0.001
Marital status (married/cohabiting), n (%)* 29 (50.9) 94 (94.9) o 0.001
Drug use by mothers during pregnancy – ASSIST total score, median (range)w
Total score for nicotine 17.50 (0-31) 0.00 (0-39) o 0.001
Total score for alcohol 4.00 (0-33) 0.00 (0-11) o 0.001
Total score for cannabis 0.00 (0-25) - -
Presence of current psychopathology in mothers, n (%)
MINI positive for any diagnosis 25 (61.0) 32 (33.3) 0.005
Biomarkers (general linear models), adjusted mean (95%CI)
BDBF, umbilical cord blood= 3.86 (2.29-5.43) 0.85 (0.47-1.23) o 0.001
TBARS, umbilical cord blood (mM MDA)y 63.97 (39.43-88.50) 177.04 (140.93-213.14) o 0.001
TBARS, maternal peripheral blood (mM MDA)|| 30.52 (17.79-43.25) 29.21 (23.95-34.47) 0.86
BDNF, maternal peripheral blood (ng/mL)z 4.03 (2.87-5.18) 6.67 (5.60-7.74) 0.006
Data presented as mean (standard deviation), unless otherwise specified.
95% confidence interval = 95%CI; ASSIST = Alcohol, Smoking and Substance Involvement Screening Test; BDNF = brain-derived
neurotrophic factor; IQ = intelligence quotient; MINI = Mini International Neuropsychiatric Interview; SD = standard deviation;
TBARS = thiobarbituric acid reactive substances.
*Fisher’s exact test. w Mann-Whitney U test.
=Adjusted for intensity of alcohol, tobacco, and cannabis use in the last 3 months, presence of any maternal infection, infant weight,
and marital status.
yAdjusted for intensity of alcohol, tobacco, and cannabis use in the last 3 months, presence of any maternal psychopathology,
maternal infectious disease (HIV, syphilis, and/or hepatitis C), prenatal care, marital status, and estimated IQ.
|| Adjusted for intensity of cannabis use in the last 3 months, presence of any maternal psychopathology, and 5-minute Apgar.
zAdjusted for intensity of use of alcohol and tobacco.
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system, including CART, and into the impact of drug use on
pregnancy.
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